AMAT
41
5
FDX
37
-2
GWW
41
-9
DHI
43
-11
ADM
34
-2
K
54
-2
GS
65
2
ROK
40
9
SHW
50
2
CMG
44
-30
BEN
34
-2
PSX
50
-2
TRIP
52
5
BAC
60
-3
GILD
63
-2
TMO
46
2
COP
54
-8
TJX
53
9
FOX
59
2
DUK
67
-18
AMAT
41
5
FDX
37
-2
GWW
41
-9
DHI
43
-11
ADM
34
-2
K
54
-2
GS
65
2
ROK
40
9
SHW
50
2
CMG
44
-30
BEN
34
-2
PSX
50
-2
TRIP
52
5
BAC
60
-3
GILD
63
-2
TMO
46
2
COP
54
-8
TJX
53
9
FOX
59
2
DUK
67
-18
Financhill
Back

EyePoint Pharmaceuticals 10K Form

Sell
30

EYPT
EyePoint Pharmaceuticals

Last Price:
$6.25
Seasonality Move:
16.96%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive EYPT News And Ratings

See the #1 stock for the next 7 days that we like better than EYPT

EYPT Financial Statistics

Sales & Book Value

Annual Sales: $43.3M
Cash Flow: $-36.2M
Price / Cash Flow: 0
Annual Sales: $4.93
Price / Book: 1.25

Profitability

EPS (TTM): -2.31000
Net Income (TTM): $-130.9M
Gross Margin: $39.6M
Return on Equity: -50.34%
Return on Assets: -37.87%

EyePoint Pharmaceuticals Earnings Forecast

Key EyePoint Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 17 years for EYPT is 91.42%.
  • The Selling, General & Administrative Expenses for EYPT have been equal to 121.30% of Gross Profit Margin.
  • The Research & Development expenses have been 307.18% of Revenue.
  • The Net Earning history of EYPT is -302.43% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 10 years.

EyePoint Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: EYPT
CUSIP: 30233G
Website: eyepointpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.81
Quick Ratio: 7.57

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EYPT Technical Analysis vs Fundamental Analysis

Sell
30
EyePoint Pharmaceuticals (EYPT) is a Sell

Is EyePoint Pharmaceuticals a Buy or a Sell?